AR037907A1 - Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 - Google Patents
Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6Info
- Publication number
- AR037907A1 AR037907A1 ARP020104952A ARP020104952A AR037907A1 AR 037907 A1 AR037907 A1 AR 037907A1 AR P020104952 A ARP020104952 A AR P020104952A AR P020104952 A ARP020104952 A AR P020104952A AR 037907 A1 AR037907 A1 AR 037907A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- independently
- aryl
- alkyl
- alkyl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
El uso del mismo para el tratamiento terapéutico de trastornos relacionados con, o afectados, por el receptor de 5-HT6. Reivindicación 1: Un compuesto de fórmula (1), en donde: W es SO2, CO, CONR11 o CSR12; X es N o CR1; Y es N o CR2; Z es N o CR3; Q es N o CR4, con la condición de que no más de dos de X, Y, Z y Q pueden ser N; n es un entero de 2 o 3; R1, R2, R3 y R4 son cada uno, de manera independiente, H, halógeno, CN, OCO2R13, CO2R14, CONR15R16, CNR17NR18R19, SOmR20, NR21R22, OR23, COR24, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; R5 y R6 son cada uno independientemente H o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; o R5 y R6 se pueden tomar junto con el átomo al cual están unidos, para formar un anillo de 5 a 7 miembros opcionalmente sustituido, que de manera opcional contiene un heteroátomo adicional seleccionado entre O, N o S; R7 y R8 son cada uno de manera independiente, H o un grupo alquilo C1-6 opcionalmente sustituido; R9 es H, halógeno, o un grupo alquilo C1-6, alcoxi C1-6, arilo o heteroarilo, cada uno opcionalmente sustituido; R10 es un grupo arilo, heteroarilo o alquilo C1-6, opcionalmente sustituido, o un sistema de anillo bicíclico o tricíclico de 8 a 13 miembros opcionalmente sustituido que tiene un átomo N en la cabeza de puente y que opcionalmente contiene 1, 2 o 3 heteroátomos adicionales seleccionados entre N, O o S, con la condición de que cuando Q es N y X, Y y Z son CH, entonces R10 debe ser diferente de fenilo; m es 0 o un entero de 1 o 2 ; R11 y R12 son cada uno de manera independiente, H o un grupo alquilo C1-6, arilo o heteroarilo, cada uno opcionalmente sustituido; R13, R14, R20 y R24 son cada uno de manera independiente H, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; R15, R16 y R23 son cada uno de manera independiente H, o un grupo alquilo C1-6 opcionalmente sustituido; y R17, R18, R19, R21 y R22 son cada uno de manera independiente H, o un grupo alquilo C1-4, opcionalmente sustituido; o R21 y R22 se pueden tomar junto con el átomo al cual están unidos para formar un anillo de 5 a 7 miembros que opcionalmente contiene otro heteroátomo seleccionado entre O, N o S; o los estereoisómeros del mismo o las sales farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34283801P | 2001-12-20 | 2001-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037907A1 true AR037907A1 (es) | 2004-12-22 |
Family
ID=23343489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104952A AR037907A1 (es) | 2001-12-20 | 2002-12-18 | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US6800640B2 (es) |
| EP (1) | EP1456206B1 (es) |
| JP (1) | JP4339123B2 (es) |
| KR (1) | KR20040077861A (es) |
| CN (1) | CN1620455A (es) |
| AR (1) | AR037907A1 (es) |
| AT (1) | ATE396191T1 (es) |
| AU (1) | AU2002360618B2 (es) |
| BR (1) | BR0215151A (es) |
| CA (1) | CA2470832C (es) |
| CO (1) | CO5590960A2 (es) |
| DE (1) | DE60226775D1 (es) |
| DK (1) | DK1456206T3 (es) |
| ES (1) | ES2305338T3 (es) |
| IL (1) | IL162242A0 (es) |
| MX (1) | MXPA04005886A (es) |
| NO (1) | NO20043099L (es) |
| PL (1) | PL370890A1 (es) |
| RU (1) | RU2004122094A (es) |
| TW (1) | TW200301251A (es) |
| WO (1) | WO2003053970A1 (es) |
| ZA (1) | ZA200405733B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2222828B1 (es) | 2003-07-30 | 2006-04-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos. |
| US7592340B2 (en) | 2003-12-04 | 2009-09-22 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| UY28945A1 (es) | 2004-06-09 | 2006-01-31 | Glaxo Group Ltd | Derivados de pirrolopiridina |
| MX2007002076A (es) | 2004-09-03 | 2007-03-29 | Yuhan Corp | Derivados de pirrolo [3,2-c] piridina y procesos para su preparacion. |
| AU2005280740B2 (en) * | 2004-09-03 | 2011-04-28 | Yuhan Corporation | Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof |
| KR101142363B1 (ko) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
| EP1947085A1 (en) * | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| CN101678014B (zh) * | 2007-05-21 | 2012-12-12 | Sgx药品公司 | 杂环激酶调节剂 |
| CN101730680A (zh) * | 2007-05-24 | 2010-06-09 | 记忆医药公司 | 具有5-ht6受体亲和力的4’取代的化合物 |
| US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| EP2356116A1 (en) * | 2008-11-20 | 2011-08-17 | OSI Pharmaceuticals, Inc. | Substituted pyrroloý2,3-b¨-pyridines and-pyrazines |
| WO2011019634A2 (en) * | 2009-08-10 | 2011-02-17 | Taipei Medical University | Aryl substituted sulfonamide compounds and their use as anticancer agents |
| AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
| US20130072495A1 (en) | 2010-05-14 | 2013-03-21 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| EP2714688B1 (en) * | 2011-05-26 | 2016-02-24 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
| KR101916928B1 (ko) | 2011-07-22 | 2018-11-08 | 글락소스미스클라인 엘엘씨 | 조성물 |
| KR20150046267A (ko) | 2012-08-24 | 2015-04-29 | 글락소스미스클라인 엘엘씨 | 피라졸로피리미딘 화합물 |
| EP2922550B1 (en) | 2012-11-20 | 2017-04-19 | Glaxosmithkline LLC | Novel compounds |
| EA028480B1 (ru) | 2012-11-20 | 2017-11-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Новые соединения |
| US9428512B2 (en) | 2012-11-20 | 2016-08-30 | Glaxosmithkline Llc | Compounds |
| CN102977094A (zh) * | 2012-11-30 | 2013-03-20 | 盛世泰科生物医药技术(苏州)有限公司 | 一种2-羟基-1,5-萘啶的合成方法 |
| CN104725295B (zh) | 2013-12-20 | 2019-05-24 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
| AU2015286049B2 (en) | 2014-07-08 | 2018-03-01 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977131A (en) | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| DE69937372T2 (de) * | 1999-04-21 | 2008-06-26 | Nps Allelix Corp., Mississauga | Piperidin-indol derivate mit 5-ht6 affinität |
| DE60011269T2 (de) * | 1999-08-12 | 2005-06-23 | Nps Allelix Corp., Mississauga | Azaidole mit serotonin rezeptor affinität |
| US6476034B2 (en) | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
| KR100985140B1 (ko) * | 2001-12-20 | 2010-10-05 | 와이어쓰 엘엘씨 | 5-하이드록시트립타민-6 리간드로서의 인돌릴알킬아민 유도체 |
| KR20070088770A (ko) * | 2004-12-14 | 2007-08-29 | 와이어쓰 | 신경변성 장애의 치료 및 예방을 위한 5-ｈｔ6 작용제의용도 |
-
2002
- 2002-12-04 TW TW091135173A patent/TW200301251A/zh unknown
- 2002-12-17 JP JP2003554686A patent/JP4339123B2/ja not_active Expired - Fee Related
- 2002-12-17 BR BR0215151-0A patent/BR0215151A/pt not_active IP Right Cessation
- 2002-12-17 PL PL02370890A patent/PL370890A1/xx unknown
- 2002-12-17 IL IL16224202A patent/IL162242A0/xx unknown
- 2002-12-17 MX MXPA04005886A patent/MXPA04005886A/es active IP Right Grant
- 2002-12-17 AU AU2002360618A patent/AU2002360618B2/en not_active Ceased
- 2002-12-17 DE DE60226775T patent/DE60226775D1/de not_active Expired - Lifetime
- 2002-12-17 WO PCT/US2002/040220 patent/WO2003053970A1/en active Application Filing
- 2002-12-17 EP EP02795890A patent/EP1456206B1/en not_active Expired - Lifetime
- 2002-12-17 AT AT02795890T patent/ATE396191T1/de not_active IP Right Cessation
- 2002-12-17 DK DK02795890T patent/DK1456206T3/da active
- 2002-12-17 RU RU2004122094/04A patent/RU2004122094A/ru not_active Application Discontinuation
- 2002-12-17 KR KR10-2004-7009710A patent/KR20040077861A/ko not_active Application Discontinuation
- 2002-12-17 CN CNA02828173XA patent/CN1620455A/zh active Pending
- 2002-12-17 CA CA2470832A patent/CA2470832C/en not_active Expired - Fee Related
- 2002-12-17 ES ES02795890T patent/ES2305338T3/es not_active Expired - Lifetime
- 2002-12-18 AR ARP020104952A patent/AR037907A1/es not_active Application Discontinuation
- 2002-12-19 US US10/323,263 patent/US6800640B2/en not_active Expired - Fee Related
-
2004
- 2004-06-15 CO CO04055770A patent/CO5590960A2/es not_active Application Discontinuation
- 2004-07-19 ZA ZA200405733A patent/ZA200405733B/en unknown
- 2004-07-19 NO NO20043099A patent/NO20043099L/no not_active Application Discontinuation
- 2004-08-19 US US10/922,678 patent/US7297705B2/en not_active Expired - Fee Related
-
2007
- 2007-11-16 US US11/941,479 patent/US7585876B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60226775D1 (de) | 2008-07-03 |
| CA2470832C (en) | 2010-09-21 |
| CA2470832A1 (en) | 2003-07-03 |
| RU2004122094A (ru) | 2005-03-27 |
| CN1620455A (zh) | 2005-05-25 |
| AU2002360618A1 (en) | 2003-07-09 |
| US7585876B2 (en) | 2009-09-08 |
| US7297705B2 (en) | 2007-11-20 |
| ES2305338T3 (es) | 2008-11-01 |
| CO5590960A2 (es) | 2005-12-30 |
| US20030171395A1 (en) | 2003-09-11 |
| WO2003053970A1 (en) | 2003-07-03 |
| ZA200405733B (en) | 2005-10-19 |
| EP1456206B1 (en) | 2008-05-21 |
| US20050020598A1 (en) | 2005-01-27 |
| BR0215151A (pt) | 2004-10-19 |
| US20080114023A1 (en) | 2008-05-15 |
| AU2002360618B2 (en) | 2009-01-08 |
| JP2005519046A (ja) | 2005-06-30 |
| JP4339123B2 (ja) | 2009-10-07 |
| TW200301251A (en) | 2003-07-01 |
| US6800640B2 (en) | 2004-10-05 |
| IL162242A0 (en) | 2005-11-20 |
| EP1456206A1 (en) | 2004-09-15 |
| KR20040077861A (ko) | 2004-09-07 |
| ATE396191T1 (de) | 2008-06-15 |
| NO20043099L (no) | 2004-08-17 |
| PL370890A1 (en) | 2005-05-30 |
| DK1456206T3 (da) | 2008-09-08 |
| MXPA04005886A (es) | 2004-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR040566A1 (es) | Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6 | |
| AR040567A1 (es) | Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6 | |
| AR043180A1 (es) | Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6 | |
| AR037906A1 (es) | Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| CO5650164A2 (es) | Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR061651A1 (es) | Analogos de piridina ii | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| PE20030809A1 (es) | Derivados de piperidina como antagonistas de la hormona concentradora de la melanina (mch) | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
| AR054799A1 (es) | Derivados de oxindol | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |